Growing Ovarian Cancer Awareness Drives the Demand for Ovarian Cancer Diagnostics Market

The market is expanding due to the rising demand for early cancer detection due to growing ovarian cancer awareness. The increase in mortality rates among female populations is largely due to ovarian cancer, which will drive market expansion during the forecast period. Ovarian and cyst cancer is on the rise due to several reasons, including genetic alterations and environmental influences. Ovarian cancer is a cancer that affects the ovaries, which are responsible for generating eggs in women. As a result, improved diagnostic processes and techniques are needed to determine the stage of cancer to treat. Furthermore, the rising mortality rate from ovarian cancer is alarming, emphasizing the importance of early detection to provide treatment. The increased awareness of ovarian cancer is expected to be a driving factor for market growth.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-ovarian-cancer-diagnostics-market

Data Bridge Market Research analyses that the Ovarian Cancer Diagnostics Market is expected to grow at a CAGR of 7.0% in the forecast period of 2023 to 2030 and is expected to reach USD 11,647.12 million by 2030 from USD 6517.51 million in 2022.

Key Findings of the Study

Ovarian Cancer Diagnostics Market

Rising screening tests for the detection of diseases are expected to drive the market growth

Exams and screening tests are used to detect the diseases such as cancer in persons who are asymptomatic. There has been a lot of study done to create an ovarian cancer screening test, but so far there hasn't been much success. Transvaginal ultrasound (TVUS) and the CA-125 blood test are the two procedures most frequently used to screen for ovarian cancer, in addition to a thorough pelvic exam. TVUS is a test that inserts an ultrasound wand into the vagina to use sound waves to look at the uterus, fallopian tubes and ovaries. It can aid in the discovery of an ovarian mass (tumor), but it is unable to determine if a mass is cancerous or benign. The CA-125 blood test quantifies the level of the CA-125 protein in the blood. A lot of ovarian cancer patients have high CA-125 values. This test can be helpful as a tumor marker to assist direct treatment in women who have been diagnosed with ovarian cancer because a high level frequently decreases if treatment is effective. However, measuring CA-125 levels is not as helpful as an ovarian cancer screening test. Therefore, it is anticipated that the rise in better diagnostic processes and techniques will serve as a driving force for market expansion.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Product Type (Instruments, Kits and Reagents), Procedure Type (Biopsy Test, Medical Imaging Test, Blood Markers Testing and Genetic Testing), Cancer Type (Germ Cell, Epithelial Tumor and Stromal Cell Tumor), End User (Cancer Diagnostic Centers, Hospital Laboratories, Research Institutes and Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN (Germany), Quest Diagnostics Incorporated. (U.S.), Hologic, Inc. (U.S.), Arbor Vita Corporation (U.S.), Guided Therapeutics, Inc. (U.S.), CooperSurgical Inc (U.S.), BD (U.S.), Cardinal Health (U.S.), Siemens Healthcare Private Limited (Germany), Zilico (U.K.), GenomeMe Lab Inc. (Canada), Exact Sciences Corporation (U.S.), Fujirebio (Japan), Advaxis Inc. (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K.), Bristol-Myers Squibb Company (U.S.), Merck & Co., Inc (U.S.)

Data Points Covered in the Report

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

Global ovarian cancer diagnostics market is categorized into four notable segments based on product type, procedure type, cancer type, and end user.

  • Based on product type, the market is segmented into instruments, kits and reagents.

Instruments segment is expected to dominate the ovarian cancer diagnostics market

Instruments segment is expected to dominate the market with 70.27% market share as this type of product is utilized in various regions.

  • Based on procedure type, the market is segmented into biopsy tests, medical imaging test, blood markers testing and genetic testing.

Blood markers testing segment is expected to dominate the ovarian cancer diagnostics market

Blood markers testing segment is expected to dominate the market with 40.41% market share as this type of procedure is utilized in various regions.

  • Based on cancer type, the market is segmented into germ cell, epithelial tumor, and stromal cell tumor. Epithelial tumor segment is expected to dominate the market with 58.70% market share as this type of cancer is highly prevalent.
  • Based on end user, the market is segmented into cancer diagnostic centers, hospital laboratories, research institutes, and others. Cancer diagnostic centers segment is expected to dominate the market with 46.83% market share due to the accurate results and quick detection, which is highly preferred by the manufacturers.

Major Players

Data Bridge Market Research recognizes the following companies as the major ovarian cancer diagnostics market players in ovarian cancer diagnostics market are Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN (Germany), Quest Diagnostics Incorporated. (U.S.), Hologic, Inc. (U.S.), Arbor Vita Corporation (U.S.), Guided Therapeutics, Inc. (U.S.), CooperSurgical Inc (U.S.), BD (U.S.), Cardinal Health (U.S.), Siemens Healthcare Private Limited (Germany), Zilico (U.K.), GenomeMe Lab Inc. (Canada), Exact Sciences Corporation (U.S.), Fujirebio (Japan), Advaxis Inc. (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K.), Bristol-Myers Squibb Company (U.S.), Merck & Co., Inc (U.S.)

Ovarian Cancer Diagnostics Market

Market Development

  • In 2022, Myriad Genetics Inc. announced that it had acquired Gateway Genomics, LLC. The purchase expands access to tailored genetic tests for women both during and after the reproductive stage of life, strengthening Myriad Genetics' portfolio of women's health products. Myriad will see an increase in revenue as a result of serving pregnant women earlier with SneakPeek and providing data-driven genetic insights throughout their lifetime with the Prequel non-invasive prenatal screen, Foresight carrier screen, and MyRisk Hereditary Cancer Test with Risk Score for all ancestries.
  • In October 2022, Quest Diagnostics and Decode Health announced the beginning of a new phase of their partnership. The two companies developed RNA (transcriptome) sequencing capabilities during this phase based on their respective next-generation sequencing, analytics, and clinical expertise. The partnership is important because biomarker-based information can speed up the development of new diagnostic tools and discover potential cancer medication targets while also lowering the cost of these endeavours (breast, prostate and ovarian cancer). Through this partnership, the business is better able to explore novel R&D avenues and expand its global reach.

Regional Analysis

Geographically, the countries covered in the ovarian cancer diagnostics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

As per Data Bridge Market Research analysis:

North America is the dominant region in ovarian cancer diagnostics market in the forecast period 2023 - 2030

North America is dominating due to growing R&D investments and the introduction of new products are increasing the market due to the high prevalence and incidence of neurological illnesses in the area.

Asia-Pacific is estimated to be the fastest-growing region in ovarian cancer diagnostics market in the forecast period 2023 - 2030

Asia-Pacific is expected to dominate the global ovarian cancer diagnostics market due to the owing to factors such as overall economic development, improvement in healthcare infrastructure, an increase in disposable income, and a rise in consumer awareness. During the forecast period, the ovarian cancer diagnostics market in emerging countries such as China, India, and South Korea is expected to grow rapidly.

COVID-19 Impact Analysis

The COVID-19 pandemic impacted healthcare systems worldwide, disrupting routine care in many facilities and exposing vulnerable cancer patients to significant risks. Coronavirus disease (COVID-19) begins to spread globally in early 2020. Ovarian cancer patients should be considered at high risk of developing severe morbidity from COVID-19. The majority of them are diagnosed at an advanced stage of disease. The coronavirus outbreak is affecting ovarian cancer patients' care; surgeries, treatments, scheduled physician appointments, laboratory tests, and imaging are all being cancelled or delayed. Higher levels of cancer, anxiety, and depression were associated with younger age, presumed immune compromised and delay in cancer care. Providers must collaborate with patients to balance the increased risks of coronavirus and cancer, while also acknowledging that communication is a critical clinical tool for improving quality of life. The coronavirus pandemic has presented oncologists with unprecedented challenges. Treatments are interrupted, surgeries are cancelled and regular oncology evaluations are rescheduled for cancer patients. Cancer patients and their doctors must weigh the risks of coronavirus disease 2019 and cancer treatment against the consequences of postponing cancer treatment. As a result, the COVID-19 pandemic was expected to have an impact on market growth during the forecast period.

For more detailed information about the ovarian cancer diagnostics market report, click here – https://www.databridgemarketresearch.com/reports/global-ovarian-cancer-diagnostics-market